Pfizer Inc.
Financials
Valuation Metrics
Pfizer Inc.'s Market Cap is $157.30B. At end of 2025 it was $139.17B. Ranked #100 of 3,121 in US market (top 3%), #64 of 1,658 on NYSE (top 4%), #10 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 4%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $157.30B | US#100/3,121 Sec#10/266 |
| Revenue | $63.70B | US#94/3,121 Sec#5/266 |
| Net Income | $4.33B | US#181/3,121 Sec#12/266 |
| Total Assets | $201.13B | US#96/3,121 Sec#1/266 |
| Net Assets | $85.19B | US#42/3,121 Sec#1/266 |
| Employees | 75,000 | US#171/3,121 Sec#5/266 |
| Value | ||
| P/E | 36.29x | US#1,733/3,121 Sec#46/266 |
| P/B | 1.85x | US#1,134/3,121 Sec#40/266 |
| P/S | 2.47x | US#1,490/3,121 Sec#36/266 |
| EV/EBITDA | 17.39x | US#1,749/3,121 Sec#46/266 |
| FCF Yield | 6.98% | US#1,024/3,121 Sec#32/266 |
| Profitability | ||
| ROE | 5.09% | US#1,826/3,121 Sec#57/266 |
| ROA | 2.16% | US#1,606/3,121 Sec#63/266 |
| Op. Margin | 25.08% | US#685/3,121 Sec#33/266 |
| Revenue Growth | -0.21% | US#2,267/3,121 Sec#133/266 |
| Earnings Growth | -59.69% | US#1,775/3,121 Sec#48/266 |
| Financial Health | ||
| Debt Ratio | 135.74% | US#1,393/3,121 Sec#180/266 |
| Total Debt | $63.19B | US#70/3,121 Sec#2/266 |
| FCF | $10.99B | US#77/3,121 Sec#9/266 |
| Cash | $976M | US#704/3,121 Sec#32/266 |
| Current Ratio | 1.27x | US#1,920/3,121 Sec#250/266 |
| Net Debt/EBITDA | 4.93x | US#2,006/3,121 Sec#75/266 |
| Dividend | ||
| Div. Yield | 6.22% | US#199/3,121 Sec#4/266 |
| Div. Growth | 2.38% | US#1,034/3,121 Sec#19/266 |
| Performance | ||
| 1Y Return | 18.25% | US#1,195/3,121 Sec#159/266 |
| 1M Return | -2.27% | US#784/3,121 Sec#80/266 |
| From 52W High | -5.51% | US#338/3,121 Sec#26/266 |
| 1Y MDD | -17.09% | US#489/3,121 Sec#15/266 |
| Trading | ||
| Volume | 23,905,475 shares | US#82/3,121 Sec#5/266 |
| Trading Value | $658M | US#183/3,121 Sec#10/266 |
| Per Share | ||
| EPS | $0.76 | US#1,768/3,121 Sec#53/266 |
| BPS | $14.95 | US#1,532/3,121 Sec#49/266 |
Company Info
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.